Previous 10 | Next 10 |
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today ann...
$165 million in manufacturing grants awarded to ARCALIS by the Japanese government Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infect...
2023-10-02 12:28:56 ET More on BioNTech BioNTech: Renewed COVID Focus Might Spark Potential Share Price Boost BioNTech: Not Just Another Jab In The Arm BioNTech SE (BNTX) Q2 2023 Earnings Call Transcript Updated COVID boosters to divide America Pfizer...
2023-09-26 12:37:33 ET More on Arcturus Therapeutics Arcturus: mRNA Therapies For Rare Diseases Accelerate Towards Proof Of Concept Arcturus, CSL granted EU review for COVID vaccine Arcturus Therapeutics' joint venture, ARCALIS bags $115M from Japanese government ...
CF Foundation Increases Financial Commitment to ~$25 Million Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines ...
Late-breaking data presented at 9 th ESWI Influenza Conference in Valencia Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious...
2023-09-07 05:35:06 ET Summary Results from phase 2 study using ARCT-810 for the treatment of patients with Ornithine-Transcarbamylase [OTC] deficiency are expected in the coming months. The Ornithine-Transcarbamylase Deficiency market is expected to reach $930.33 million by 2030....
2023-09-05 16:00:00 ET Summary Arcturus Therapeutics specializes in mRNA medicines, targeting infectious diseases and rare disorders using proprietary technologies. Despite a financial dip post-Q2 2023, Arcturus remains financially strong, with significant focus and potential in m...
2023-09-05 10:13:43 ET More on Arcturus, CSL, etc. CSL: Watch Out For Positive Surprises CSL Limited ( OTCQX:CSLLY ) Q4 2023 Earnings Call Transcript CSL Limited 2023 Q4 - Results - Earnings Call Presentation Arcturus Therapeutics Holdings Inc. ( ARCT...
EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response compared to Comirnaty® and superiority of ARCT-154 in neutralizing antibody response aga...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...